We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

18 hedge funds and large institutions have $1.7M invested in Evoke Pharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

13% more funds holding

Funds holding: 16 → 18 (+2)

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

28% less capital invested

Capital invested by funds: $2.35M → $1.7M (-$660K)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$35.5K
2
CAN
Cetera Advisor Networks
California
+$19.6K
3
Victory Capital Management
Victory Capital Management
Texas
+$10.2K
4
BlackRock
BlackRock
New York
+$5.95K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.31K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.84K
2
Morgan Stanley
Morgan Stanley
New York
-$1.34K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$560K – – –
SOMRS
2
State of Michigan Retirement System
Michigan
$464K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$236K +$2.31K +12 +0.9%
Creative Planning
4
Creative Planning
Kansas
$116K – – –
BlackRock
5
BlackRock
New York
$70K +$5.95K +31 +8%
California Public Employees Retirement System
6
California Public Employees Retirement System
California
$43K – – –
Northern Trust
7
Northern Trust
Illinois
$39K – – –
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$37K – – –
WA
9
Wambolt & Associates
Colorado
$37K – – –
CAN
10
Cetera Advisor Networks
California
$33K +$19.6K +102 +109%
Citadel Advisors
11
Citadel Advisors
Florida
$31K +$35.5K +185 New
UCFA
12
United Capital Financial Advisors
Texas
$18K – – –
Victory Capital Management
13
Victory Capital Management
Texas
$8K +$10.2K +53 New
Morgan Stanley
14
Morgan Stanley
New York
$1K -$1.34K -7 -70%
Citigroup
15
Citigroup
New York
$1K – – –
LC
16
Lindbrook Capital
California
$1K – – –
UBS Group
17
UBS Group
Switzerland
– -$3.84K -20 -91%
Wells Fargo
18
Wells Fargo
California
– +$192 +1 New

EVOK Hedge Fund Activity: Q1 2020 in Review

18 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2020, worth a combined $1.7M — down 28% from $2.35M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $35.5K. The largest seller was UBS Group, cutting an estimated $3.84K.

  • 18 institutional investors held Evoke Pharma (EVOK) as of Q1 2020, up from 16 in Q4 2019.
  • Funds reported $1.7M of Evoke Pharma stock for Q1 2020, down 28% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q1 2020 and 0 closed out, a net change of +3 holders.
  • The largest Evoke Pharma buyer in Q1 2020 was Citadel Advisors, an estimated $35.5K added.
  • The largest Evoke Pharma seller in Q1 2020 was UBS Group, an estimated $3.84K sold.

Based on aggregated 13F filings for Q1 2020.